Trident (TRID)

Sector: Textile /Small Cap | Earnings Update – 3QFY19

Background: Trident Ltd was incorporated in the year 1990, headquartered in Ludhiana, Punjab. Company operates in three key business segments such as Home textile (49% of revenue), Yarn (33% of revenue) and Paper (18% of revenue) with manufacturing facilities located in Punjab and Madhya Pradesh. Company has a capacity to produce 90,000 MTPA of terry towel, 43.2mn mtrs of bed linen, 115,200 MTPA of yarn and 175,000 TPA of wheat straw based paper. Between FY15-18, Company's Revenue and PAT grew at a CAGR of 6.7% and 3.8% to INR 45.6bn and INR 2.6bn respectively.

• Trident's revenue grew by 18%YoY to INR 12.9bn; Textile revenue grew by 18.6%	YoY to INR
INR 70.7 10.3bn, aided by strong in the home textile segment and Paper revenue grew 15.7%	6 YoY to INR
2.59bn. Bed linen revenue grew 41.7% YoY, aided by 33.3% YoY increase in volume a	
BUY increase in realization. Bath linen grew 10.1% YoY, aided by volume growth of 12.2 realization de-grew by 2.1% YoY.	% YOY, While
During the guarter, EBITDA stood at INR 2.68bn, grew 18.2% YoY; EBITDA margins re	mained flat at
NR 91.4/51 20.8%; Gross margin improved by 450bps YoY, which got offset by higher emplo	yee cost and

- 20.8%; Gross margin improved by 450bps YoY, which got offset by higher employee cost and operating expenditures. Employee cost increased by 260bps YoY and other expenses was higher by 140bps YoY. Interest expenses were higher by 17% YoY to INR 294mn. Depreciation expenses were down by 12% YoY. Other income grew by 249% YoY. PAT grew by 53.6%YoY to INR 1,121mn; PAT margin improved by 270bps YoY to 10.2%.
- Textile division EBIT margin stood at 10.5% up 180bps YoY; while Paper division EBIT margin stood at 38.1% up 910bps on low base.
- Bed linen capacity utilization improved 300bps sequentially to 64%, while Bath linen capacity utilization declined 700bps QoQ to 46%.Yarn and Paper division capacity utilization remained flat sequential at 97% and 90% respectively.
- Company's net debt stood at INR21.97bn with net debt to equity of INR 0.7X.
- Board has approved to implement co-gen steam (2X150 TPH) and power plant (2X30 MW) facility in Budni with a total capex of INR 5.5bn, financed by internal accrual and borrowing of INR 3.75bn. The project will be executable in phased manner and expected to be completed by FY21.

Valuation: Trident is the second largest Terry towel manufacturer and largest wheat straw based paper manufacturer in India. We introduce FY21 estimates and we expect Revenue, EBITDA and EPS to grow at a CAGR of 6.7%, 8% and 13.9% respectively between FY19-21E, as the operating and financial leverage plays out. As the company has completed all major capital expenditures, we estimate the cumulative FCF generated between FY19-21E would be around INR 20.9bn i.e. ~58% of current market capitalization, which provides a good margin of safety. At CMP, Trident is trading at 9.1X & 7.8X FY20E & FY21E earnings and we rollover the valuation to FY21E and revise the target price upwards to INR 90 valuing the company at 10X FY21E EPS, while maintaining the **BUY** rating. **Risks:** Loss in market share in terry towel segment, adverse price movement in currency and cotton prices and withdrawal of export schemes by Gol.

Results Summary 3QFY19

3QFY19	3QFY18	YoY Growth	2QFY19	QoQ Growth
12,914	10,941	18.0%	13,915	-7.2%
2,686	2,273	18.2%	2,611	2.9%
892	1,013	-12.0%	917	-2.7%
294	252	16.5%	260	13.2%
150	43	248.6%	98	52.7%
529	320	65.3%	441	20.0%
1,121	730	53.6%	1,091	2.7%
1,317	819	60.9%	1,130	16.6%
20.8	20.8		18.8	
32.1	30.5		28.8	
10.2	7.5		8.1	
	12,914 2,686 892 294 150 529 1,121 1,317 20.8 32.1	12,914 10,941 2,686 2,273 892 1,013 294 252 150 43 529 320 1,121 730 1,317 819 20.8 20.8 32.1 30.5	12,914 10,941 18.0% 2,686 2,273 18.2% 892 1,013 -12.0% 294 252 16.5% 150 43 248.6% 529 320 65.3% 1,121 730 53.6% 1,317 819 60.9% 20.8 20.8 32.1	12,914 10,941 18.0% 13,915 2,686 2,273 18.2% 2,611 892 1,013 -12.0% 917 294 252 16.5% 260 150 43 248.6% 98 529 320 65.3% 441 1,121 730 53.6% 1,091 1,317 819 60.9% 1,130 20.8 20.8 18.8 32.1 30.5 28.8

Trident —— Relative SENSEX (RHS)

+91-44-30007361

Sathyanarayanan M


```
Sensex 36,321 Strong operational performance
```

Chola

Nifty			10,890	
Price		I	NR 70.7	
Target Price (12M)			INR 90	
Recommendation			BUY	
52 Week High/Low		INR	91.4/51	
Bloomberg / Reuters		TRID IN /TRIE.BO		
Equity (shares in mn)		509.6		
Mkt. Cap in bn		INR 36/\$ 0.51 1,095.98		
Avg. Daily Vol. (`000)				
Avg. Daily Vol. (mn)		INR 77.	4/\$ 1.09	
Shareholding	Dec 17	Sep 18	Dec 18	
Promoters (%)	67.77	68.45	70.77	
FII (%)	1.50	1.35	1.45	
DII (%)	2.37	2.07	0.39	
Others (%)	28.36	28.13	27.39	
Pledge (% of promoter holding)	8.69	0.00	0.00	

Valuation Summary (INR bn)

, (,				
Y/E March	2019E	2020E	2021E	
Revenue	50.5	54.1	57.5	
EBITDA	9.5	10.2	11.1	
Adj PAT	3.5	4.0	4.6	
Adj EPS	6.9	7.8	9.0	
% growth	33.9	12.4	15.5	
PE	10.2	9.1	7.8	
P/ BV	1.1	1.0	1.0	
EV/EBITDA	5.6	4.8	3.9	
EV/Sales	1.1	0.9	0.8	
Div Yield (%)	2.4	2.9	3.4	
ROE (%)	11.6	12.0	12.7	
Performance %	1M	3M	12M	
Trident	7.94	21.3	-21.5	
Sensex	-0.3	3.2	3.7	
100			110	



sathyanarayananm@chola.murugappa.com





DISCLOSURES/ APPENDIX I. ANALYST CERTIFICATION

I, Sathyanarayanan M hereby certify (1) that the views expressed in this research report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this research report, (2) No part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by Cholamandalam Securities Limited or its Group/associates companies. (3) has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

II. ISSUER SPECIFIC REGULATORY DISCLOSURES, Unless specifically mentioned in Point No. 9 below:

1. The Research Analyst(s), Cholamandalam Securities Limited (CSL), Associate of Analyst or his relative does not have any financial interest in the company(ies) covered in this report.

2. The Research Analyst, CSL or its associates or relatives of the Research Analyst associates collectively do not hold more than 1% of the securities of the company (ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.

3. The Research Analyst, his associate, his relative and CSL do not have any other material conflict of interest at the time of publication of this research report.

4. The Research Analyst, CSL and its associates have not received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in this report, in the past twelve months.

5. The Research Analyst, CSL or its associates have not managed or co-managed in the previous twelve months, a private or public offering of securities for the company (ies) covered in this report. \

6. CSL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party, in connection with the research report.

7. The Research Analyst has not served as an Officer, Director or employee of the company (ies) covered in the Research report.

8. The Research Analyst and CSL has not been engaged in market making activity for the company(ies) covered in the Research report.

9. Details CSL, Research Analyst and its associates pertaining to the companies covered in the Research report:

Sr.No.	Particulars	Yes/No
1	Whether compensation has been received from the company(ies) covered in the Research report in the past 12 months for investment banking transaction by CSL	No
2	Whether Research Analyst, CSL or its associates or relatives of the Research Analyst associates collectively hold more than 1% of the company(ies) covered in the Research report	No
3	Whether compensation has been received by CSL or its associates from the company(ies) covered in the Research report	No
4	CSL or its associates have managed or co-managed in the previous twelve months a private or public offering of securities for the company(ies) covered in the Research report	No
5	Research Analyst, his associate, CSL or its associates have received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in the Research report, in the last twelve month	No

10. There are no material disciplinary action that been taken by any regulatory authority impacting equity research analysis activities.

STOCK RATINGS

- Q -

BUY : The stock's total return is expected to exceed 15 % over the next 12 months.

OUT PERFORMER: The stock's total return is expected to be within 5-15% over the next 12 months.

MARKET PERFORMER : The stock's total return is expected to be between -5% to +5% over the next 12 months.

UNDER PERFORMER: The stock's total return is expected to be between -15% to -5% over the next 12 months.

SELL: The stock's total return is expected to more than -15% over the next 12 months.

III. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable, but we do not represent that it is accurate or complete, and one should exercise due caution while acting on it. Descriptions of any company or companies or their securities mentioned herein are not complete and this document is not, and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments.

Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to CSL or its associates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently send or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United State (to U.S.Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof.

Any unauthorized use, duplication, redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the Report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

CSL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, CSL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member

of any companies that the analysts cover. Our salespeople, traders, and other professionals or associates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by CSL however, compensation may relate to the revenue of CSL, of which sales and trading are a part. Research analysts and sales persons of CSL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. CSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc

CSL and its associates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the Company may or may not subscribe to the views expressed therein.

CSL, its associates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall CSL, any of its associates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The Company accepts no liability whatsoever for the actions of third parties.

The Report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Report refers to website material of the Company, the Company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the Company shall be at your own risk and the Company shall have no liability arising out of, or in connection with, any such referenced website

CSL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall the CSL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by CSL through this presentation.

Neither CSL, nor any of its other group companies or associates, shall be responsible for any decisions taken on the basis of this report. Investors are advised to consult their Investment and Tax consultants before taking any investment decisions based on this report.

RESEARCH							
Sathyanarayanan M	Consumption	+91-44 - 4004 7361	sathyanarayananm@chola.murugappa.com				
Mugilan K	Technicals	+91-44 - 4004 7353	mugilank@chola.murugappa.com				
Keerthi S	Banking & Financial Services	+91-44 - 4004 7363	keerthi@chola.murugappa.com				
Sai Lavanya K	IT, Auto & Auto Ancillary	+91-44 - 4004 7266	sailk@chola.murugappa.com				
Sahil Jain	Associate - Cement	+91-44 - 4004 7360	sahilj@chola.murugappa.com				
Muthu Kumar J	Associate	+91-44 - 4004 7360	muthukumarj@chola.murugappa.com				
	INSTITUTIONAL SALES						
Venkat Chidambaram	Head of FII Business & Corporate Finance*	+91-44 - 24473310	venkatc@chola.murugappa.com				
Kishore K Ganti	Mumbai	+91-22-26597239	kishorekg@chola.murugappa.com				
Bhavesh Katariya	Mumbai	+91-9860297739	bhaveshgk@chola.murugappa.com				
Sudhanshu Kumar	Institutional Equities*	+91 - 9953175955	sudhanshuk@chola1.murugappa.com				
Balaji H	Compliance Officer	044 - 30007226	balajih@chola.murugappa.com				

*Employees of Business Partner - RCCR

murugappa